CN101175768B - 促红细胞生成素变体 - Google Patents

促红细胞生成素变体 Download PDF

Info

Publication number
CN101175768B
CN101175768B CN2006800165436A CN200680016543A CN101175768B CN 101175768 B CN101175768 B CN 101175768B CN 2006800165436 A CN2006800165436 A CN 2006800165436A CN 200680016543 A CN200680016543 A CN 200680016543A CN 101175768 B CN101175768 B CN 101175768B
Authority
CN
China
Prior art keywords
leu
epo
polynucleotide
disease
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800165436A
Other languages
English (en)
Chinese (zh)
Other versions
CN101175768A (zh
Inventor
安德烈亚斯·迈泽莱斯
约瑟夫·普里勒尔
克里斯特尔·博纳斯
乌尔里希·迪纳格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charité – Universitätsmedizin Berlin
Original Assignee
Charité – Universitätsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité – Universitätsmedizin Berlin filed Critical Charité – Universitätsmedizin Berlin
Publication of CN101175768A publication Critical patent/CN101175768A/zh
Application granted granted Critical
Publication of CN101175768B publication Critical patent/CN101175768B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800165436A 2005-05-13 2006-05-15 促红细胞生成素变体 Expired - Fee Related CN101175768B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010473.6 2005-05-13
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants
PCT/EP2006/004564 WO2006120030A1 (en) 2005-05-13 2006-05-15 Erythropoietin variants

Publications (2)

Publication Number Publication Date
CN101175768A CN101175768A (zh) 2008-05-07
CN101175768B true CN101175768B (zh) 2013-09-11

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800165436A Expired - Fee Related CN101175768B (zh) 2005-05-13 2006-05-15 促红细胞生成素变体

Country Status (12)

Country Link
EP (2) EP1736481A1 (enExample)
JP (1) JP5231214B2 (enExample)
KR (1) KR101468737B1 (enExample)
CN (1) CN101175768B (enExample)
AU (1) AU2006245916B2 (enExample)
BR (1) BRPI0608769A2 (enExample)
CA (1) CA2608379C (enExample)
DK (1) DK1885747T3 (enExample)
ES (1) ES2457398T3 (enExample)
RU (1) RU2430162C2 (enExample)
WO (1) WO2006120030A1 (enExample)
ZA (1) ZA200709091B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
US20100267576A1 (en) * 2007-05-02 2010-10-21 University Of Utah Research Foundation Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CN105072914B (zh) 2013-02-06 2018-09-21 Nc医学研究公司 用于治疗神经变性的细胞疗法
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
HK1257024A1 (zh) 2015-08-31 2019-10-11 宾夕法尼亚大学 用於治疗伴侣动物的aav-epo
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
US11566056B2 (en) 2020-05-26 2023-01-31 Sylus Co., Ltd Peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
CA3222471A1 (en) * 2021-06-15 2022-12-22 Giovanni MARFIA Epo variants and modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043382A2 (en) * 2002-11-08 2004-05-27 Egea Biosciences, Inc. Enhanced variants of erythropoietin and methods of use

Also Published As

Publication number Publication date
WO2006120030A1 (en) 2006-11-16
KR20080021595A (ko) 2008-03-07
ZA200709091B (en) 2009-08-26
CN101175768A (zh) 2008-05-07
JP2008539745A (ja) 2008-11-20
ES2457398T3 (es) 2014-04-25
EP1885747B1 (en) 2013-11-20
WO2006120030A8 (en) 2006-12-28
EP1736481A1 (en) 2006-12-27
CA2608379C (en) 2014-12-16
RU2430162C2 (ru) 2011-09-27
RU2007146455A (ru) 2009-06-20
CA2608379A1 (en) 2006-11-16
KR101468737B1 (ko) 2014-12-09
JP5231214B2 (ja) 2013-07-10
AU2006245916A1 (en) 2006-11-16
DK1885747T3 (en) 2014-02-24
BRPI0608769A2 (pt) 2010-01-26
AU2006245916B2 (en) 2012-03-15
EP1885747A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
US7423139B2 (en) High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20200299348A1 (en) Cell-permeable bone morphogenetic protein (cpbmp) recombinant protein and use thereof
CA2779562C (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
US20190106470A1 (en) Erythropoietin variants
EP1885747B1 (en) Erythropoietin variants
BR112013023010B1 (pt) Polipeptídeo isolado, ácido nucleico isolado que codifica o polipeptídeo, vetor de expressão, processo para a produção de um polipeptídeo isolado e composição farmacêutica compreendendo o polipeptídeo
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
CN108473546A (zh) Mg53突变体及其制备方法和用途
JP7834347B2 (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
KR102682612B1 (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
JP2002509691A (ja) 生物学的活性が改変された組換えタンパク質多量体の製造及び使用
JP2009517009A (ja) エリスロポエチンポリペプチド及びそれらの使用
JP2003500053A (ja) 血管内皮増殖因子ダイマー
KR20040089093A (ko) 시스틴-결절 폴드 단백질
JP2001515719A (ja) Ｍｐｌリガンド類似体
JP7355828B2 (ja) ヒトＬｅｆｔｙ Ａタンパク質変異体を含む融合タンパク質及びその用途
US6835381B1 (en) Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
WO2010102380A1 (en) Potent vegf antagonists
KR101330033B1 (ko) 인간 과립구 콜로니 자극 인자(ｇ-ｃｓｆ)의 변이체를 포함하는 허혈성 질환 치료용 약학 조성물
EP1192181B1 (en) Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor
TW202200606A (zh) C4結合蛋白之C端片段與血管生成素-1之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及Tie2促效劑
TW202146429A (zh) Ｃ４結合蛋白之ｃ端片段與血管生成素－１之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及ｔｉｅ２促效劑
JP2003532623A (ja) 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法
JP2008519593A (ja) ロイシンリッチリピート（ｌｒｒ）モチーフ含有タンパク質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130911

Termination date: 20180515

CF01 Termination of patent right due to non-payment of annual fee